Objective
Every year around 350.000 patients in the EU are newly diagnosed with colorectal cancer (CRC). Although € 1.4 Billion are
spent on CRC drugs, the majority of patients fail to respond to therapy because their individual tumor is resistant to the
chosen treatment. These patients suffer from unwanted side effects and after two month are switched to another drug
regime – giving rise to additional drug and hospital costs. 2cureX ApS, a Danish SME, has developed IndiTreat, an ex-vivo
chemosensitivity test. The functional profiling test uses 3D-cellular “micro-tumors” prepared directly from a patient’s tumor. It
allows the selection of the most effective and least toxic drug regimen for each individual patient prior to initiating treatment.
For the oncologists and patients this greatly improves the probability of selecting an effective drug treatment.
The main objective of MicroCaT is to clinically validate the benefits of IndiTreat in an interventional multi-national study with
metastatic (stage IV) colorectal cancer patients. Demonstrating the clinical utility and cost effectiveness of IndiTreat will pave
the way for uptake in EU clinical guidelines and reimbursement arrangements. Communication and dissemination of
MicroCaT project activities will be key to raise the consciousness of this breakthrough innovation with clinicians, patients and
health assessment authorities. Commercializing IndiTreat for CRC patients will enable 2cureX to significantly grow and
expand its business. With the potential to predict therapy responses in all solid forms of cancer, the use of IndiTreat will
eventually result in multi-millions of health care costs savings as well as improving the quality of life of cancer patients across
Europe.
Fields of science (EuroSciVoc)
CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques. See: https://op.europa.eu/en/web/eu-vocabularies/euroscivoc.
CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques. See: https://op.europa.eu/en/web/eu-vocabularies/euroscivoc.
- medical and health sciences basic medicine immunology
- medical and health sciences clinical medicine oncology colorectal cancer
- medical and health sciences clinical medicine oncology pancreatic cancer
You need to log in or register to use this function
We are sorry... an unexpected error occurred during execution.
You need to be authenticated. Your session might have expired.
Thank you for your feedback. You will soon receive an email to confirm the submission. If you have selected to be notified about the reporting status, you will also be contacted when the reporting status will change.
Programme(s)
Multi-annual funding programmes that define the EU’s priorities for research and innovation.
Multi-annual funding programmes that define the EU’s priorities for research and innovation.
-
H2020-EU.3.1. - SOCIETAL CHALLENGES - Health, demographic change and well-being
MAIN PROGRAMME
See all projects funded under this programme -
H2020-EU.3.1.3. - Treating and managing disease
See all projects funded under this programme
Topic(s)
Calls for proposals are divided into topics. A topic defines a specific subject or area for which applicants can submit proposals. The description of a topic comprises its specific scope and the expected impact of the funded project.
Calls for proposals are divided into topics. A topic defines a specific subject or area for which applicants can submit proposals. The description of a topic comprises its specific scope and the expected impact of the funded project.
Funding Scheme
Funding scheme (or “Type of Action”) inside a programme with common features. It specifies: the scope of what is funded; the reimbursement rate; specific evaluation criteria to qualify for funding; and the use of simplified forms of costs like lump sums.
Funding scheme (or “Type of Action”) inside a programme with common features. It specifies: the scope of what is funded; the reimbursement rate; specific evaluation criteria to qualify for funding; and the use of simplified forms of costs like lump sums.
SME-2 - SME instrument phase 2
See all projects funded under this funding scheme
Call for proposal
Procedure for inviting applicants to submit project proposals, with the aim of receiving EU funding.
Procedure for inviting applicants to submit project proposals, with the aim of receiving EU funding.
(opens in new window) H2020-SMEInst-2016-2017
See all projects funded under this callCoordinator
Net EU financial contribution. The sum of money that the participant receives, deducted by the EU contribution to its linked third party. It considers the distribution of the EU financial contribution between direct beneficiaries of the project and other types of participants, like third-party participants.
2100 Kobenhavn
Denmark
The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.
The total costs incurred by this organisation to participate in the project, including direct and indirect costs. This amount is a subset of the overall project budget.